logo
Plus   Neg
Share
Email

Baxter International Inc. (BAX) Is Down Sharply On FDA News

Baxter International Inc. (BAX) and Halozyme Therapeutics (HALO) announced Monday morning that the FDA has requested additional information to complete its review of the HyQ Biologics License Application.

Baxter International has gapped open sharply lower Monday and is now down 3.38 at $54.65. The stock has dropped to a 2 1/2 month low and has fallen below its 200-day moving average.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Follow RTT